FDA 483 - Kumar Organic Products Limited - April 21, 2023

An FDA inspection conducted at Kumar Organic Products Limited in Vadodara, Gujarat, India, from April 17 to April 21, 2023, revealed significant deficiencies in the company's materials system. The primary observation, noted as a repeat from a 2019 inspection, focused on the inadequate establishment of reliability for component supplier reports of analyses. Specifically, the firm failed to sufficiently validate supplier test results, thereby compromising the completeness of its supplier qualification process. Instances included using multiple components in products shipped to the United States without thoroughly verifying the suppliers' certificates of analysis. Additionally, Kumar Organic Products Limited qualified a new supplier for critical components without performing a full verification of their certificate of analysis. These components are used in products destined for further processing in the U.S. As documented in the FDA Form 483, these observations indicate a need for the manufacturer to implement robust corrective actions. The company is expected to address these findings to ensure the reliability of its raw material quality controls and compliance with regulatory expectations for pharmaceutical manufacturing.